Wells Fargo’s Regeneron Pharmaceuticals REGN Stock Holding History

Wells Fargo’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-100	Closed	-$96.2K	–	7361
2024 Q1	$96.2K	Hold	100	–	–	﹤0.01%	4919
2023 Q4	$87.8K	Hold	100	–	–	﹤0.01%	4983
2023 Q3	$82.3K	Hold	100	–	–	﹤0.01%	4900
2023 Q2	$71.9K	Hold	100	–	–	﹤0.01%	5229
2023 Q1	$82.2K	Buy	+100	New	+$75.4K	﹤0.01%	4907
2022 Q4	–	Sell	-9,100	Closed	-$6.27M	–	7675
2022 Q3	$6.27M	Buy	+9,100	New	+$5.73M	﹤0.01%	1838
2017 Q1	–	Sell	-6,000	Closed	-$57K	–	6463
2016 Q4	$57K	Hold	6,000	–	–	﹤0.01%	5345
2016 Q3	$90K	Hold	6,000	–	–	﹤0.01%	4978
2016 Q2	$270K	Buy	+6,000	New	+$2.31M	﹤0.01%	4243

Other funds holding REGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Wells Fargo's REGN Position: Q2 2026 in Review

Wells Fargo reduced its Regeneron Pharmaceuticals (REGN) stake by 0.86% in Q2 2026, selling an estimated $830K and leaving 140,802 shares worth $87.8M. The position accounts for 0.01% of the portfolio, ranked #733.

Wells Fargo first reported a position in REGN in Q2 2013 and has held it in 53 quarters since. The position peaked at $580M in Q2 2015. 1,335 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

Wells Fargo held 140,802 shares of Regeneron Pharmaceuticals worth $87.8M as of Q2 2026.
Wells Fargo sold 1,219 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $830K.
Regeneron Pharmaceuticals made up 0.01% of Wells Fargo's portfolio in Q2 2026, its #733 holding.
Wells Fargo first reported a position in Regeneron Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
Wells Fargo's Regeneron Pharmaceuticals position peaked at $580M in Q2 2015.
1,335 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.